title: Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.
authors.affiliation: San Martino Hospital, Genoa, Italy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Del Mastro
authors.affiliation: San Gerardo Hospital, Monza, Italy.
authors.forename: Marina
authors.initials: M
authors.lastname: Cazzaniga
authors.affiliation: Molinette Hospital, Turin, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Solidoro
authors.affiliation: Cremona Hospital, Cremona, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Generali
authors.affiliation: Istituto Nazionale Tumori, Milan, Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Bianchi
authors.affiliation: Cremona Hospital, Cremona, Italy.
authors.forename: Franco
authors.initials: F
authors.lastname: Testore
authors.affiliation: University Federico II Hospital, Naples, Italy.
authors.forename: Sabino
authors.initials: S
authors.lastname: De Placido
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019468:Disease Management; D000068338:Everolimus / Q000008:administration & dosage; D005260:Female; D006801:Humans; D055118:Medication Adherence; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
chemical_list: D000068338:Everolimus; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
keywords: adverse events; breast cancer; compliance; dosing; everolimus; management; multidisciplinary follow-up; toxicity